Science & Technology
AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44NS145814-01
Award Ceiling
$1.3M
Award Floor
$1.3M
Close Date
Jul 31, 2027
503 days leftTotal Funding
$1.3M
Expected Awards
1
Posted Date
Aug 27, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44NS145814-01
Description
SBIR Phase Phase II award: "AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma" awarded to MERLIN THERAPEUTICS INC in King of Prussia, Pennsylvania. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,256,291. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.